Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab

Inclusion Criteria: * Participants at least 18 years old at diagnosis of clinically palpable stage III resectable melanoma * Participants treated with nivolumab+relatimab (nivo+rela) or nivolumab+ipilimumab (nivo+ipi) in the neoadjuvant setting * Participants with at least 6 months of follow-up from initiation of neoadjuvant therapy, unless deceased prior to 6 months of follow-up Exclusion Criteria: * Participants received nivo+rela or nivo+ipi for clinically palpable stage III resectable melanoma as part of a therapeutic clinical trial * Participants had history of diagnosis of any malignancy (except for non-melanoma skin cancer) in the last 2 years. * Participants received adjuvant nivo+rela or adjuvant nivo+ipi after neoadjuvant nivo+ipi * Participants received adjuvant nivo+ipi after neoadjuvant nivo+rela * Participants received any systemic therapy prior to the initiation of neoadjuvant nivo+rela or nivo+ipi